Competitive inhibition studies on HER-2/neu+ tumours utilizing both FRP5- and HB8696-derived scFvs (one FITC-conjugated and the other nonlabelled) could probably clarify whether these recognise the same or different HER-2/neu epitopes. This evidence concerns the gene ERBB2 and neoplasm.